- Home
- DOYU vs ENGN Comparison
DOYU vs ENGN Comparison
Compare DOYU & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- ENGN
- Stock Information
- Founded
- DOYU 2014
- ENGN 1999
- Country
- DOYU China
- ENGN Canada
- Employees
- DOYU N/A
- ENGN N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- ENGN
- Sector
- DOYU Technology
- ENGN
- Exchange
- DOYU Nasdaq
- ENGN Nasdaq
- Market Cap
- DOYU 312.9M
- ENGN 317.6M
- IPO Year
- DOYU 2019
- ENGN N/A
- Fundamental
- Price
- DOYU $15.51
- ENGN $7.00
- Analyst Decision
- DOYU Strong Sell
- ENGN Strong Buy
- Analyst Count
- DOYU 3
- ENGN 9
- Target Price
- DOYU $7.03
- ENGN $29.78
- AVG Volume (30 Days)
- DOYU 193.2K
- ENGN 108.9K
- Earning Date
- DOYU 11-20-2024
- ENGN 03-10-2025
- Dividend Yield
- DOYU N/A
- ENGN N/A
- EPS Growth
- DOYU N/A
- ENGN N/A
- EPS
- DOYU N/A
- ENGN N/A
- Revenue
- DOYU $631,661,209.00
- ENGN N/A
- Revenue This Year
- DOYU N/A
- ENGN N/A
- Revenue Next Year
- DOYU N/A
- ENGN N/A
- P/E Ratio
- DOYU N/A
- ENGN N/A
- Revenue Growth
- DOYU N/A
- ENGN N/A
- 52 Week Low
- DOYU $6.29
- ENGN $4.42
- 52 Week High
- DOYU $20.17
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- DOYU 75.80
- ENGN 46.61
- Support Level
- DOYU $10.25
- ENGN $6.32
- Resistance Level
- DOYU $16.08
- ENGN $7.70
- Average True Range (ATR)
- DOYU 0.50
- ENGN 0.98
- MACD
- DOYU 0.56
- ENGN -0.01
- Stochastic Oscillator
- DOYU 89.07
- ENGN 38.98
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.